AdaptHealth Corp. Form 8-K Summary
Business Context and Reporting Period
Company: AdaptHealth Corp.
Filing Date: June 24, 2020
Reporting Period: Current Report (Event Date: June 24, 2020)
Context: The filing details a series of material definitive agreements with Deerfield Partners and Deerfield Private Design Fund IV ("Deerfield") to restructure equity holdings and secure financing in connection with the pending acquisition of Solara Holdings, LLC ("Solara").
Key Financial Metrics and Capital Structure Changes
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The financial impact is limited to capital structure transactions:
- Exchange Transaction: Deerfield Private Design Fund IV exchanged 15,810,547 shares of Class A Common Stock for 158,105.47 shares of non-voting Series B-1 Convertible Preferred Stock.
- Proposed Investment: Deerfield Partners agreed to purchase $35,000,000 of Series B-2 Convertible Preferred Stock at $1,000 per share.
- Liquidity Context: The Series B-2 investment is expected to close contemporaneously with a separate $190 million issuance of Series A Preferred Stock and Class A Common Stock.
- Debt: The filing does not disclose specific debt levels or liquidity ratios.
Material Changes Versus Prior Period
The filing represents a material change in the Company's capitalization and shareholder rights:
- Equity Restructuring: Conversion of a significant block of common stock held by Deerfield into non-voting preferred stock (Series B-1).
- Registration Rights Amendment: Deerfield's obligations regarding underwriter lockups in future public offerings were limited to a maximum of two occasions, capped at 60 days, with a termination date of November 8, 2021.
- Acquisition Financing: The transactions are conditioned on the closing of the Solara acquisition, which was previously announced in a May 29, 2020 filing.
Guidance, Outlook, Risks, and Contingencies
Outlook and Conditions:
- The closing of the $35 million Series B-2 investment is contingent upon the satisfaction of conditions related to the Solara acquisition, including the absence of a material adverse effect and the consummation of the OEP Investment.
- Stockholder approval is required to remove conversion restrictions on the Series B-2 Preferred Stock to comply with Nasdaq Listing Rule 5635.
- The Company has secured voting agreements from stockholders holding over 50% of voting power to approve the necessary stockholder actions.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks such as judicial proceedings, competitive conditions, and the impact of the COVID-19 pandemic.
- Regulatory Approval: Transactions are subject to Nasdaq review and the filing of a preliminary proxy statement.
- Lockup Restrictions: Deerfield Partners will be restricted from transferring the Series B-2 Preferred Stock or underlying common stock for 60 days following the closing of the investment.
Key Facts for Investor Verification
- Verify the closing status of the Solara acquisition, as the $35 million Deerfield investment is contingent upon it.
- Confirm the timeline for the stockholder meeting required to approve the removal of conversion restrictions on Series B-2 Preferred Stock.
- Review the full text of the Exchange Agreement (Exhibit 10.1) and Investment Agreement (Exhibit 10.2) for specific anti-dilution adjustments and conversion mechanics.
- Monitor the filing of the preliminary proxy statement, which must occur within 30 days of receiving Solara's audited financial statements or 15 days after the Deerfield Investment closes.
- Check for the simultaneous closing of the $190 million Series A/Common Stock issuance mentioned as a condition for the Deerfield Investment.